within Pharmacolibrary.Drugs.ATC.J;

model J01XA01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.0833333333333335e-06,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00035999999999999997,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00029,
    k12             = 0.044,
    k21             = 0.044
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01XA01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Vancomycin is a glycopeptide antibiotic used mainly for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacteria. It is often reserved for infections that do not respond to other antibiotics and is approved and widely used today especially in hospital settings.</p><h4>Pharmacokinetics</h4><p>Adult healthy volunteers, intravenous administration, standard dosage.</p><h4>References</h4><ol><li><p>Lindley, B, et al., &amp; Young, DC (2022). Pharmacokinetics of intermittent dosed intravenous vancomycin in adult persons with cystic fibrosis. <i>Pediatric pulmonology</i> 57(11) 2646–2651. DOI:<a href=\"https://doi.org/10.1002/ppul.26077\">10.1002/ppul.26077</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35836330/\">https://pubmed.ncbi.nlm.nih.gov/35836330</a></p></li><li><p>Moellering, RC (1984). Pharmacokinetics of vancomycin. <i>The Journal of antimicrobial chemotherapy</i> 14 Suppl D 43–52. DOI:<a href=\"https://doi.org/10.1093/jac/14.suppl_d.43\">10.1093/jac/14.suppl_d.43</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6394577/\">https://pubmed.ncbi.nlm.nih.gov/6394577</a></p></li><li><p>Palmer, LB, et al., &amp; Smaldone, GC (2025). Pharmacokinetics of vancomycin in sputum of intubated patients: Optimized intravenous delivery vs. inhaled therapy. <i>British journal of clinical pharmacology</i> 91(1) 127–133. DOI:<a href=\"https://doi.org/10.1111/bcp.16225\">10.1111/bcp.16225</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39235040/\">https://pubmed.ncbi.nlm.nih.gov/39235040</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01XA01;
